Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics (Ingelheim, Germany, Oxford, UK, and Boston, USA, Feb 26, 2026) by Linda Ruckel and Dr Reinhard Malin. The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells Deal includes upfront and milestone payments to Sitryx totaling over US $500